Aduhelm

News

FDA whittles back Aduhelm approval amid concern over broad l...

One of the criticisms levelled at the FDA over its approval of Biogen and Eisai's Alzheimer's disease drug Aduhelm was its decision to clear use of the drug in a broader group of patients t

News

ICER revises its view of Aduhelm's price – but not by much

The Institute for Clinical and Economic Review (ICER) was very damning of Biogen's new Alzheimer's disease therapy Aduhelm when it issued its first report on the drug last month, and a swif

News

Amid outcry over Aduhelm price, Biogen says it may consider ...

Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer's therapy Aduhelm – but only if its assumptions on population size and uptake are differe

News

Consumer group seeks resignation of top FDA staffers over Ad...

With the first patient set to receive Biogen's new Alzheimer's drug Aduhelm in Rhode Island today, US consumer advocacy organisation Public Citizen is deeply unhappy about the FDA's approva

News

Closeup of X-ray photography of human brain

And then there were three: another FDA adcomm member quits o...

The fallout over the FDA's decision to approved Biogen's Alzheimer's therapy Aduhelm continues to be felt, with a third member of its advisory committee resigning in protest.

News